# Bodycote account plan

> Bodycote is the world's largest heat treatment and thermal processing provider, with 136 sites in 22 countries and £727.1m of FY 2025 revenue.

## At a glance

Bodycote plc describes itself as the world's largest provider of heat treatment and specialist thermal processing: it treats customers' metal components with heat, pressure and surface technologies to make them stronger and more durable. It ran 136 operational sites in 22 countries with more than 50 processes and 4,127 average employees in FY 2025, serving Aerospace & Defence, Automotive, Energy, Industrial Markets and Consumer, Medical & Other customers. FY 2025 revenue was £727.1m (-4.0%) and adjusted operating profit £114.3m at a 15.7% margin. Listed on the London Stock Exchange, it agreed on 1 September 2026 to a recommended cash acquisition by Vulcan Alpha Bidco, owned by funds managed by Veritas Capital, expected to complete in Q1 2027, after which the shares will be delisted.

## Business units

- **Specialist Technologies** (29% of FY 2025 Group revenue (£212.3m)): Differentiated processes including Hot Isostatic Pressing (HIP), HIP Product Fabrication, Specialty Stainless Steel Processes (S3P) and Surface Technology coatings, with a 27.1% margin in FY 2025. In H1 2026 revenue rose 16.7% organically to £121.2m, and A&D, up 37%, is now 50% of the division. The target is for the division to reach 35-40% of revenue by 2028.
- **Precision Heat Treatment** (63% of FY 2025 Group revenue (£459.3m)): Controlled heating and cooling of metals in industrial furnaces, including vacuum heat treatment, Nitriding, Corr-I-Dur® and low-pressure carburising, serving automotive, A&D and industrial customers. The FY 2025 margin fell to 16.0% on weak automotive and industrial volumes; H1 2026 revenue was £250.8m, +6.4% organic, at a 15.0% margin.
- **Non-Core** (8% of FY 2025 Group revenue (£55.5m)): Older, less efficient plants being merged, closed or sold under the Optimise programme. Ten French automotive and industrial sites were sold in November 2025, and H1 2026 revenue fell 71.6% to £9.2m.

## Strategic priorities

- **Optimise, Perform, Grow targets for 2028**: Specialist Technologies at 35-40% of revenue, operating margins above 20% by 2028, mid-single-digit revenue growth, ROCE of 15-20% and 80-90% cash conversion through the cycle.
- **Exit non-core sites**: Optimise covers 31 sites; 27 were done by H1 2026 and 29 are expected by end-2026, targeting at least £15m run-rate benefits by mid-2027. A second wave aimed at structurally declining automotive markets, especially Western Europe, is being explored.
- **Operational excellence**: The Perform programme rolls out lean tools from four lighthouse sites in North America and Europe and targets c.100bps of margin improvement by 2028.
- **Grow in aerospace, defence and IGT**: Sales were reorganised into global end-market teams with key account management; target end markets (A&D, IGT, medical, electronics) reached 48% of Group revenue in H1 2026, and the European defence pipeline is >10x current annual European defence sales.
- **Decarbonisation**: A 46% reduction in Scope 1 and 2 CO2 emissions by 2030 versus 2019, with zero-emission plants in Derby and Rotherham and a customer carbon calculator.

## Latest results

In H1 2026 (six months to 30 June) Group revenue rose 3.3% to £381.2m (6.5% organic) and adjusted operating profit 10.7% to £61.0m, with the margin up 110bps to 16.0%. Core revenue grew 9.6% organically, led by A&D (+25%), IGT (+11%) and Consumer, Medical & Other (+15%), while Automotive fell 4%. Adjusted EPS rose 18.3% to 25.2p and the interim dividend to 7.2p. Full-year guidance is unchanged: Core organic growth led by A&D and IGT, moderating in H2, with capex at or towards the lower end of £80-90 million.

## Investments and deals

- **Growth projects**: Capex was £77.0m in FY 2025 and £33.5m in H1 2026, funding an S3P greenfield in South Korea, a plant in Mexico (go-live 2027), HIP capacity expansions in Europe and North America and two North American A&D site upgrades.
- **Bolt-on acquisitions**: Spectrum Thermal Processing, an aerospace-focused heat treater in Rhode Island, was acquired in January 2026 for c.£6m; the pipeline counts over 100 targets, with a preference for off-market deals with family-owned firms.
- **Divestment of French sites**: Ten French automotive and industrial sites were sold in November 2025 for net proceeds of £19m.
- **Share buyback**: A new £80m buyback runs to end-2027, after close to £100m was returned to shareholders in 2025.
- **Take-private by Veritas Capital**: Veritas agreed an Offer Value of 940p per share, valuing Bodycote at about £1,640m fully diluted, with completion expected in Q1 2027 and a Business Evaluation of the automotive and general industrial businesses within about 12 months of completion.

## Challenges and risks

- **Structural decline in automotive**: Western European automotive was down high single digit in H1 2026, and the Board cited structural challenges in certain Automotive and Industrial markets as a meaningful risk to its medium-term targets.
- **Oil & Gas weakness**: Oil & Gas revenue in Specialist Technologies fell c.40% in FY 2025 after a significant customer project ended.
- **Energy-intensive, fixed-cost base**: Energy is about 10% of revenue and utility costs were £70.3m in 2025; a high share of short-term fixed costs makes profit sensitive to volumes.
- **Margin headwinds from growth projects and pay**: Variable pay and new-site ramp-up each cut about 100bps from H1 2026 Core margins, with ramp-up costs fading through 2027-2028.
- **Ownership change**: The Veritas acquisition will delist the shares and may lead to divestment of parts of the automotive and general industrial Precision Heat Treatment businesses.

## What leadership says

> "We are on track to deliver a margin improvement of 100 basis points from Perform by the year 2028 and more thereafter." — Jim Fairbairn, Chief Executive Officer, FY 2025 results presentation, 11 March 2026

> "I don't think we anticipated previously the depth of that structural challenge." — Jim Fairbairn, Chief Executive Officer, H1 2026 results presentation, 28 July 2026, on automotive

> "It is our aim every year to do several acquisitions" — Jim Fairbairn, Chief Executive Officer, H1 2026 results presentation, 28 July 2026

> "The Bodycote Board believes that this offer from Veritas reflects the high quality of Bodycote's business and management, and delivers shareholders excellent value in cash." — Daniel Dayan, Chair, Rule 2.7 announcement of the Veritas acquisition, 1 September 2026


## Where a supplier can help

- **Furnace and HIP equipment**: Tied to the growth projects: suppliers of furnaces, HIP presses and site upgrades for the South Korea S3P greenfield, the Mexico plant and the North American A&D sites.
- **Energy and decarbonisation**: Tied to the energy-intensive cost base and the 2030 emissions target: energy procurement, hedging and efficiency solutions.
- **Lean and operations tools**: Tied to the Perform programme: continuous improvement, scheduling and plant analytics tools that help deliver c.100bps of margin by 2028.
- **Key account and commercial systems**: Tied to the reorganised global end-market sales teams: CRM and pricing tools that help sell across the network to aerospace, defence and IGT customers.
- **Transaction and integration advisory**: Tied to the Veritas take-private and the site exits: advisory, integration and carve-out services for the Business Evaluation and Optimise programme.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Bodycote plc Annual Report 2025](https://www.bodycote.com/wp-content/uploads/2026/04/annual-report-2026.xhtml)

Annual report · 2026-04-16

- Bodycote is the world's largest provider of heat treatment and specialist thermal processing: 136 operational sites in 22 countries, more than 50 processes and 4,127 average employees in FY 2025, serving Aerospace & Defence, Automotive, Energy, Industrial Markets and Consumer, Medical & Other customers.
- FY 2025 Group revenue fell 4.0% to £727.1m (FY24: £757.1m); adjusted operating profit fell 11.4% to £114.3m (margin 15.7% vs 17.0%); statutory operating profit rose to £83.6m (FY24: £37.9m) on lower exceptional charges; adjusted EPS 44.4p; dividend held at 23.0p.
- Core revenue (excluding Non-Core sites being exited) was £671.6m, -0.3% organic, with H1 -3.5% and H2 +3.2%; Core adjusted operating margin 16.8% (FY24: 18.4%), hit by a c.40% fall in high-margin Oil & Gas revenue in Specialist Technologies and weak Automotive and Industrial demand.
- Divisions: Specialist Technologies 29% of revenue (£212.3m, 27.1% margin; HIP, S3P, Surface Technology), Precision Heat Treatment 63% (£459.3m, 16.0% margin), Non-Core 8% (£55.5m). Geography: Western Europe 50%, North America 38%, Emerging Markets 12%.
- Strategy "Optimise, Perform, Grow" with 2028 targets: Specialist Technologies at 35-40% of revenue, operating margin above 20%, mid-single-digit revenue growth, ROCE 15-20% and 80-90% cash conversion through the cycle.
- Optimise covers 31 sites and c.£75m Non-Core revenue: ten French automotive/industrial sites sold in November 2025 for net proceeds of £19m, eight of the other 20 Non-Core sites closed; £4m benefit in 2025 and at least £15m run-rate benefits targeted by mid-2027 for a net cash cost of £10-15m.
- Growth investment: capex £77.0m (FY24: £60.5m) for a first S3P plant in Asia, HIP capacity for A&D, two US aerospace site upgrades and an automotive greenfield in Mexico; Spectrum Thermal Processing (Rhode Island, Aerospace) acquired in January 2026; M&A pipeline of over 100 targets; European defence pipeline >10x current annual European defence sales.
- Close to £100m returned in 2025 (dividends £40.9m, buybacks £57.6m); new £80m buyback to complete by end-2027; net debt excluding leases £104.8m, about 0.6x EBITDA.
- 2026 outlook: Core organic growth led by A&D and Industrial Gas Turbines, Automotive and Industrial still challenging, operating margins to improve, partly offset by normalising variable remuneration.
- Principal risks: macro and geopolitical end-market swings on a high fixed-cost base, competition, health and safety, climate change, quality and accreditations, business interruption, cyber, investment execution and people.

### [Bodycote plc 2026 Interim Results (H1 2026)](https://www.investegate.co.uk/announcement/prn/bodycote--boy/2026-interim-results/9690269)

Interim report · 2026-07-28

- H1 2026 (to 30 June) was in line with expectations and the FY26 outlook is unchanged. Group revenue rose 3.3% to £381.2m (6.5% organic), adjusted operating profit rose 10.7% to £61.0m, and the adjusted margin rose 110bps to 16.0%.
- Core revenue was £372.0m, +9.6% organic, led by A&D (+25%), IGT (+11%) and Consumer, Medical & Other (+15%; Medical back to growth, strong semiconductor demand). Automotive fell 4%, weakest in Western Europe, and Industrial Markets were +1%.
- Specialist Technologies: revenue £121.2m (+16.7% organic), margin 26.1%. A&D, up 37% organically on programmes such as LEAP and share gains, is now 50% of the division. Two long-term agreements were renewed.
- Precision Heat Treatment: revenue £250.8m (+6.4% organic), margin flat at 15.0%, held back by low-margin transferred revenue and higher variable pay. Non-Core revenue fell 71.6% to £9.2m.
- Core margin was +30bps to 16.2% despite higher variable pay and ramp-up costs for growth projects. Adjusted EPS rose 18.3% to 25.2p and the interim dividend 4.3% to 7.2p.
- Optimise: 27 of 31 planned exits are done and a further c.£1m of improvements came in H1. Bodycote is exploring an expansion into structurally challenged Automotive and Industrial regional markets. Perform has four "lighthouse sites" and still targets c.100bps of margin by 2028.
- Grow: Spectrum acquired in January 2026 for c.£6m. Capex was £33.5m, including greenfields in South Korea and Mexico (go-live 2027), HIP expansions and two North American A&D site upgrades.
- Cash and returns: free cash flow £14.5m. Net debt excluding leases rose to £135.2m (about 0.7x) after £27.5m in dividends and £17.8m in buybacks.

### [Recommended Cash Acquisition of Bodycote plc by Vulcan Alpha Bidco (Veritas Capital) - Rule 2.7 announcement](https://www.investegate.co.uk/announcement/rns/bodycote--boy/recommended-cash-acquisition-of-bodycote-plc/9747189)

Report · 2026-09-01

- On 1 September 2026, Vulcan Alpha Bidco, a company owned by funds managed by Veritas Capital (New York, ~$54bn AUM), and Bodycote agreed a recommended cash acquisition at an Offer Value of 940p per share: 932.8p in cash plus the 7.2p FY26 interim dividend.
- The cash price values Bodycote at about £1,640m fully diluted, with an enterprise value of about £1,840m. The Offer Value is a 37.5% premium to the three-month VWAP of 683.4p before the 22 May 2026 possible-offer announcement.
- The deal followed an unsolicited approach by Apollo, announced 22 May 2026, then competing proposals from Veritas and CVC (CVC's best was 915p, Veritas's 914p) before Veritas raised its offer to 940p on 31 August.
- The Board recommends unanimously. It cites certain cash against macro and end-market risks, especially in automotive and industrial markets, which create "meaningful risk" to its medium-term targets.
- Veritas cites its aerospace and defence portfolio (Chromalloy, StandardAero, Frontgrade, Abaco Systems) and plans a strategy "similar to Bodycote's current strategy", with more investment and a more active M&A strategy.
- Within about 12 months of completion, a Business Evaluation will review whether parts of the automotive and general industrial Precision Heat Treatment businesses are non-core and potential divestment candidates.
- The deal is implemented by scheme of arrangement, expected to become Effective in Q1 2027 (long stop 1 September 2027). Shares will then be delisted from the LSE. Financing is Veritas equity plus committed debt.

### [Bodycote FY 2025 results presentation and Q&A transcript](https://stockanalysis.com/quote/lon/BOY/transcripts/375973-h2-2025/)

Executive talk · Jim Fairbairn, Chief Executive Officer · 2026-03-11

- FY 2025 results call (11 March 2026) with CEO Jim Fairbairn and CFO Ben Fidler. Core revenue was flat for the year (-0.3% organic) but up 3% in H2. A&D grew 14% in H2, Oil & Gas revenue fell about 25% and IGT rose 6%.
- Portfolio repositioning is the main message: 10 French sites sold, 8 closed, and Specialist Technologies moving from about a quarter to about a third of the portfolio after Optimise (target 35-40% by end-2028). Faster-growth markets reach 45% after Optimise.
- Optimise delivered GBP 4 million in 2025, with about GBP 4 million more in 2026, GBP 4-5 million in 2027 and the tail in 2028. Most of the remaining benefit comes from revenue retained at higher drop-through plants, mainly in Precision Heat Treatment.
- Perform targets 100bps of margin by 2028. Kaizen events cut part travel at a Cincinnati IGT site by 5 miles a week. Four lighthouse sites are planned, and the programme is mainly cost-focused.
- Growth projects worth more than $60 million in 2025-2026: S3P in South Korea, HIP in the US and France, relocation of two aerospace sites (Cincinnati, Los Angeles) and a new plant in northern Mexico.
- Capital allocation: leverage of 0.6x against a 0.5-1.5x range gives "a little bit more than GBP 200 million of firepower" for the new GBP 80 million buyback and M&A, with over 50 targets in the funnel.
- Risks: energy is about 10% of revenue (about GBP 70 million) and well hedged for two quarters; direct Middle East sales are 1%. Variable pay could be a 100bps margin headwind in 2026.
- A&D guidance is high single digit to low double digit volume growth. Aerospace is about 60% OE and 40% aftermarket.

### [Bodycote H1 2026 results presentation and Q&A transcript](https://stockanalysis.com/quote/lon/BOY/transcripts/594489-h1-2026/)

Executive talk · Jim Fairbairn, Chief Executive Officer · 2026-07-28

- H1 2026 results call (28 July 2026) with CEO Jim Fairbairn and CFO Ben Fidler: "We are on track and on plan". Core organic growth was 9.6%, with A&D up almost 25%, IGT up over 10%, Medical back to growth and Automotive down 4.4%.
- Variable pay and new-site ramp-up each cut about 100bps from H1 Core margins. The ramp-up cost continues in H2 and largely fades through 2027-2028; variable pay stays at its new base.
- Optimise may expand, focused on structurally declining auto, especially Western Europe (down high single digit). The expected payback is lower than the first wave, likely in a 2x-3x cash-cost-to-benefit range.
- M&A preference is off-market deals with family-owned firms. Bodycote declined to bid for Kittyhawk, and Spectrum and Lake City are both outperforming.
- Specialist Technologies A&D grew 37%, driven partly by GE LEAP/GEnx blade volumes (up more than 50%). Two long-term agreements were renegotiated with US Tier 1s, and the A&D team was largely rebuilt under a new president.
- Target markets (A&D, IGT, medical, electronics) are now 48% of Group revenue, up from 35% two years ago. Semis are about 2% of revenue and grew about 25%.
- An automotive site in Athens, Georgia is being converted to aerospace to serve the Huntsville space cluster. Fairbairn speaks of "a natural moat" in A&D. Nuclear and SMR work (Rolls-Royce) is a long-dated opportunity.
- Guidance: capex at the lower end of GBP 80-90 million, tax rate about 23.5%. Aerospace will moderate in H2. For 2027, OE build rates are seen rising 8%-10%.

## Questions about Bodycote

### What does Bodycote do?

Bodycote provides heat treatment and specialist thermal processing services: customers send metal components to its plants to be made stronger, more durable and more reliable. It operates 136 sites in 22 countries.

### What is Bodycote's revenue?

FY 2025 revenue was £727.1m, with adjusted operating profit of £114.3m. H1 2026 revenue was £381.2m, up 3.3%.

### How many employees does Bodycote have?

Bodycote had 4,127 average employees in FY 2025.

### Who owns Bodycote?

Bodycote is listed in London, but on 1 September 2026 its Board recommended a cash acquisition by Vulcan Alpha Bidco, owned by funds managed by Veritas Capital, expected to complete in Q1 2027.

### Who leads Bodycote?

Jim Fairbairn is CEO, Ben Fidler is CFO and Daniel Dayan chairs the Board.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
